Leavitt Partners May 2, 2023
Leavitt Partners evaluated the operational feasibility, potential benefits, and likely drawbacks of novel federal policy approaches which would establish a separate federal payment mechanism for cell and gene therapies (CGTs) delivered to Medicaid beneficiaries. The report, informed by Medicaid program experts, found several theoretical benefits to a federal program that could help to ease state budgetary pressures, but ultimately concluded that such an approach also has the potential to...
Today's Sponsors
Today's Sponsor